Abstract:Developing effective anti-fibrotic therapies for heart diseases holds the potential to address unmet needs in several cardiac conditions, including heart failure with preserved ejection fraction, hypertrophic cardiomyopathy, and cardiotoxicity induced by cancer therapy. The inhibition of the primary fibrotic regulator, transforming growth factor (TGF) β, represents an efficient strategy for mitigating fibrosis in preclinical models. However, translating these findings into clinical benefits faces challenges due to potential adverse effects stemming from TGF-β's physiological actions in inflammation and tissue homeostasis. Various strategies exist for inhibiting TGF-β, each associated with a distinct risk of adverse effects. Targeting TGF-β directly or through its signaling pathway proves efficient in reducing fibrosis. However, direct TGF-β blockade may lead to uncontrolled inflammation, especially following myocardial infarction, while interference with the signaling pathway may compromise structural integrity, resulting in issues like insufficient wound healing or ventricular dilatation. Influencing TGF-β activity through interacting signaling pathways, for instance by inhibitors of the renin–angiotensin–aldosterone-system, is insufficiently potent in reducing fibrosis. Targeting activators of latent TGF-β, including ADAMTS enzymes, thrombospondin, and integrins, emerges as a potentially safer strategy to reduce TGF-β-induced fibrosis but it requires the identification of appropriate targets. Encouragement is drawn from promising agents developed for fibrosis in other organs, fueling hope for similar breakthroughs in treating cardiac fibrosis. Such advances depend on overcoming obstacles for the implementation of anti-fibrotic strategies in patients with heart disease, including fibrosis quantification. In this review, insights garnered from interventional and mechanistic studies, obtained through a non-systemic search spanning preclinical and clinical evidence, are summarized to pinpoint the most promising targets for further exploration and development.

Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Natural polysaccharides as potential anti-fibrotic agents: A review of their progress

Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis

Physiological functions and underlying mechanisms of fibroblast growth factor (FGF) family members: recent findings and implications for their pharmacological application.

Promising small molecule anti-fibrotic agents: Newly developed or repositioned drugs targeting myofibroblast transdifferentiation

Therapeutic uses of FGFs

Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling

Potential of Plant-Derived Compounds in Preventing and Reversing Organ Fibrosis and the Underlying Mechanisms

Fibroblast growth factors as tissue repair and regeneration therapeutics

Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases

Targeting The Tgf-Beta Signaling Pathway For Fibrosis Therapy: A Patent Review (2015-2020)

Emerging Therapies for Liver Fibrosis

Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

G Protein-Coupled Receptor Kinase 2 as Novel Therapeutic Target in Fibrotic Diseases

Role of fibroblast growth factor signalling in hepatic fibrosis

Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities

From the Gut to the Lung: Evidence of Antifibrotic Activity of Endocrine Fibroblast Growth Factor 19

Targeting the TGF-β Signaling Pathway for Fibrosis Therapy: a Patent Review (2015–2020)